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Background/aim: The main aim of this study was to investigate serum total oxidant status (TOS), total antioxidant status (TAS),
oxidative stress index (OSI), and arylesterase levels in pregnant women with placenta accreta and to compare those with age-matched
healthy pregnant women.
Materials and methods: A total of 27 pregnant women who had clinically and pathologically proven placenta accreta and 30 age- and
BMI- matched healthy pregnant women were enrolled in this case control study. Maternal serum TOS, TAS, OSI, and arylesterase levels
were evaluated using logistic regression analysis to determine if there was an association with abnormal placental invasion or not.
Results: Decreased OSI (OR= 0.999, 95%CI: 0.998–1.000, P = 0.035) and increased arylesterase levels (OR= 0.981, 95%CI: 0.970–0.993,
P = 0.001) were significantly associated with the presence of placenta accreta. Maternal serum TOS, TAS, OSI, and arylesterase levels
were not predictive for adverse perinatal outcomes (P > 0.05).
Conclusions: Decreased OSI and increased arylesterase levels are significantly associated with placenta accreta and may contribute to
the abnormal invasion process.
Key words: Arylesterase, oxidative stress index, total antioxidant status, total oxidant status, placenta accreta

1. Introduction
Placenta accreta is defined as complete or partial adhesion
of the placenta to the myometrium and its incidence has
increased up to 3 per 1000 deliveries and seems to be
parallel with the increasing rate of cesarean delivery (1).
Placenta accreta is a catastrophic clinical condition that
threatens survival, due to intrapartum and postpartum
bleeding and warrants a multidisciplinary approach. The
rates of maternal mortality and morbidity with placenta
accreta have been reported to be as high as 7% and 60
%, respectively (2). While increasing cesarean sections
seem to be responsible for the increased incidence and
deficiency of decidualization, increased angiogenesis,
and overinvasiveness of the trophoblasts are implicated
in the pathophysiology of placenta accreta, the molecular
basis of this condition remains unclear (1,3). Placental
angiogenesis and trophoblastic invasion are balanced
during pregnancy. On the other hand, deterioration
of the balance between angiogenic and antiangiogenic
factors and also an imbalance between proinvasive and
* Correspondence: sibelozler@gmail.com
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antiinvasive factors might cause abnormal uteroplacental
vascularization and subsequently abnormal placental
invasion (4).
Previous studies have widely studied the impaired
growth of placental vasculature in pregnancy-associated
pathologies that lead to placental insufficiency, including
preeclampsia, intrauterine growth restriction, intrauterine
fetal demise, and miscarriage (5–8).
Additionally, it has already been proposed that as
placental circulation is established in human pregnancy,
it results in a dramatic increase in placental oxygen
levels, and thus causes an increase in reactive oxygen
species (ROS) and oxidative stress (9,10). Moreover, this
systemic oxidative damage continues until the end of
pregnancy, and so it is suggested that certain amounts of
ROS and oxidative stress are crucial for placental vascular
development throughout pregnancy (11). However, it
has been proposed that excessively increased oxidative
stress due to placental hypoxia may limit placental
angiogenesis, leading to pathologies such as IUGR and
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preeclampsia (12,13). As increased oxidative stress is
already shown to contribute in limited angiogenesis, we
suggest that increased angiogenesis in placenta accreta
may also be associated with an imbalance between oxidant
and antioxidant mechanisms.
In the current study we aimed to investigate maternal
serum TOS, TAS, OSI, and arylesterase, and antioxidant
enzyme levels in pregnant women with placenta accreta,
and to determine whether any changes in their levels
are useful in predicting adverse pregnancy outcomes in
placenta accreta.
2. Materials and methods
A case-control study was carried out between June 2013 and
May 2014 in the Obstetrics and Gynecology Department of
Zekai Tahir Burak Women’s Health Education and Research
Hospital. A total of 86 participants were included in the
study. Twenty-seven patients included in the study were
diagnosed with placenta accreta during cesarean section
and all cases were histologically confirmed according to
previously established criteria as the abnormal adherence
of placenta involving all degrees to the underlying uterine
wall (14). Thirty age- and body mass index (BMI)matched uncomplicated healthy pregnant women with
normal placental location were also recruited. Adverse
neonatal outcomes included low birthweight (<2500 g),
preterm delivery (<37 weeks), low 1- and 5-min Apgar
scores (Apgar score < 7), and neonatal intensive care
unit admission. Neonatal intensive care unit admission
criteria in our hospital are standard for all neonates and
the neonatologists did not have any information about the
present study.
Patients were excluded if any of the following disorders
were present: multiple pregnancy, preterm premature
rupture of membranes, previous pregnancy complicated
with placenta previa, any previous complicated pregnancy,
cervical or uterine surgery (myomectomy, metroplasty,
uterine septal resection, conization, any intervention for
previous pregnancy located in the lower uterine segment
having settled in the uterine scar line), thyroid dysfunction,
hypertension, epilepsy, gestational diabetes, type 1 or 2
diabetes, and patients using medication.
All participants included in the study were evaluated
at their initial admission. A clinical examination was
performed and anthropometric measurements as well as
the previous obstetric and medical history were recorded.
Gestational age was calculated from the last menstrual
period and verified by ultrasonography. Blood samples
were obtained after overnight fasting by venipuncture and
processed within 1 h of withdrawal, and all serum samples
were stored at –80 °C until the day of analysis. As oxidative
stress markers can be easily affected by other factors, we
took care that no additional factors such as concomitant
uterine contractions, bleeding, and infection were present

during the sample collection. All participants provided
written informed consent. The study protocol was
performed according to the principles of the Declaration
of Helsinki and approved by the local Ethical Committee
of our hospital.
Serum TOS and TAS levels were determined
spectrophotometrically using a method previously
described by Erel, and the results are expressed in terms of
micromolar hydrogen peroxide equivalent per liter (µmol
H2O2 eqv./L) for TOS and as millimolar trolox equivalent
per liter (mmol Trolox eqv./L) for TAS (15,16). The ratio of
TAS to TOS represents the OSI, an indicator of the degree
of oxidative stress. The OSI value is calculated according to
the formula: OSI [arbitrary unit (AU)] = TOS (µmol H2O2
eqv./L)/TAS (mmol Trolox eqv./L) × 10025. Arylesterase
activities results are expressed as kU/L serum.
2.1. Statistical analysis
IBM SPSS for Windows Version 20.0 (Armonk, NY, USA:
IBM Corp.) was used for statistical analysis. Continuous
variables were tested for normality by the Kolmogorov–
Smirnov test. Normally distributed data were presented
as mean ± standard deviations. Categorical comparisons
were performed using the chi-square test. For data not
normally distributed, median with data range (minimum
to maximum) was used. We used the independent samples
t-test and Mann–Whitney U test for parametric and
nonparametric groups, respectively. The optimal cut-off
points of laboratory parameters determining accreta were
evaluated by ROC analyses, calculating area under the
curve (AUC) as giving the maximum sum of sensitivity
and specificity for the significant test. Sensitivity and
specificity were alsocalculated at the best cut-off point for
each clinical measurement. To determine if the oxidative
stress markers are independently associated with the
presence of accreta multiple logistic regression analysis
was used. Odds ratios and 95% confidence intervals for
each independent variable were also calculated. A P value
less than 0.05 was considered statistically significant.
Multivariate logistic regression analysis was also used
to determine if a relationship between adverse neonatal
outcomes and serum oxidative stress markers was present
or not.
3. Results
Fifty-seven pregnant women were enrolled in the present
case-control study: 27 patients with placenta accreta, and
30 age- and BMI-matched healthy pregnant controls.
The baseline characteristics of the placenta accreta
patients and controls are given in Table 1. There were no
statistically significant differences in age, BMI, weight gain
in pregnancy, or the percentage of smoking between the
groups. Gravida, the percentage of preterm delivery, and
prior cesarean section history were significantly higher
in the accreta group. Maternal serum TOS and OSI were
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Table 1. Baseline characteristics and laboratory parameters of the patients with placenta accreta
and the controls.

Age (years)

Placenta accreta
n = 27

Control
n = 30

P value

28.03 ± 5.28

30.56 ± 4.99

0.070

BMI (kg/m )

28.34 ± 4.47

28.07 ± 3.12

0.797

Smoking (%)

7 (25.9%)

3 (10.3%)

0.128

2

Prior cesarean delivery (%)

20 (74.1%)

7 (23.3%)

<0.001

TAS (mmol Trolox eqv./L)

0.223 ± 0.077

0.184 ± 0.069

0.049

TOS (μmol H2O2 eqv./L)

3.144 ± 0.689

4.179 ± 1.620

0.003

OSI (arbitrary unit)

1628.43 ± 785.63

2559.30 ± 1353.23

0.003

ARES (kU/L)

420.49 ± 141.82

256.56 ± 63.95

<0.001

P value: P < 0.05 statistically significant, BMI: body mass index, TAS: total antioxidant status, TOS:
total oxidant status, ARES: arylesterase, OSI: oxidative stress index, H2O2: hydrogen peroxide

significantly lower, while TAS and arylesterase levels were
significantly higher in the accreta group when compared
with the controls (Table 1).
Serum TAS, TOS, PON, arylesterase, and OSI levels
were again evaluated with ROC analysis; cut-off levels
were determined and AUC values were calculated. The
AUC, best cut-off values, sensitivity, and specificity for
distinguishing the groups for each parameter are given
in Table 2. All parameters except TAS were found to be
statistically significant.
Multivariate logistic regression analysis was then used
to determine if there was a relationship between groups
and the defined cut-off levels of the laboratory parameters
or not. Prior cesarean delivery (OR = 0.174, 95%CI:
0.041–0.744, P = 0.018), low OSI (OR = 0.999, 95%CI:
0.998–1.000, P = 0.035), and high arylesterase levels (OR
= 0.981, 95%CI: 0.970–0.993, P = 0.001) were found to be
statistically significant in the determination of placenta
accreta (Table 3).

In addition, we examined if there were any
changes in TOS, TAS, OSI, and arylesterase levels
according to the management of placenta accreta. No
significant changes were observed when the accreta
patients were again evaluated by dividing them into
3 subgroups according to the management procedure:
hysterectomy (n = 14), compression sutures (n = 6),
and compression sutures + Bakri balloon tamponade
(n = 7).
Further analysis was also performed to determine
whether there was a correlation between oxidative
stress markers and adverse neonatal outcomes (low
APGAR, low birth weight, preterm delivery, and
neonatal unit admission) or not. Multivariate logistic
regression analysis, used to determine the predictive
value of defined cut-off levels of the laboratory
parameters and adverse perinatal outcomes, failed to
determine such an association (P > 0.05).

Table 2. Cut-off levels of TAS, TOS, OSI, and arylesterase for the prediction of placenta accreta evaluated with ROC
analysis.
Cut off
TAS (mmol Trolox eqv./L)

0.207

Sensitivity
%

Specificity
%

AUC (95%CI )

P value

0.642 (0.494–0.790)

0.066

TOS (µmol H2O2 eqv./L)

3.568

70.37%

53.33%

0.659 (0.515–0.803)

0.040

OSI (arbitrary unit)

1623.38

66.67%

80.0%

0.726 (0.592–0.860)

0.003

ARES (KU/L)

338.73

92.59%

73.33%

0.859 (0.765–0.954)

<0.001

P value: P < 0.05 statistically significant, TAS: total antioxidant status, TOS: total oxidant status, ARES: arylesterase,
OSI: oxidative stress index, AUC: area under the curve, CI: confidence interval, ROC: receiver operating characteristic,
H2O2: hydrogen peroxide
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Table 3. Multivariate logistic regression analysis of several factors for the prediction of placenta accreta.
Univariate

Multivariate

OR (95%Cl)

P value

OR (95%Cl)

P value

Prior cesarean delivery

6.667 (1.342–33.125)

0.020

0.174 (0.041–0.744)

0.018

Prior curettage

7.000 (0.501–97.751)

0.148

TAS (mmol Trolox eqv./L)

1.580 (0.809–3.813)

0.051

TOS (µmol H2O2 eqv./L)

0.497 (0.295–0.835)

0.008

1.620 (0.597–4.395)

0.343

OSI (arbitrary unit)

0.999 (0.998–1.000)

0.009

0.999 (0.998–1.000)

0.035

ARES (kU/L)

0.983 (0.973–0.993)

0.001

0.981 (0.970–0.993)

0.001

P value: P < 0.05 statistically significant, TAS: total antioxidant status, TOS: total oxidant status, ARES:
arylesterase, OSI: oxidative stress index, OR: odds ratio, CI: confidence interval, H2O2: hydrogen peroxide.

4. Discussion
In the present case-control study of oxidative stress
markers in placenta accreta, increased levels of maternal
serum arylesterase levels and decreased OSI were
found to be associated with placenta accreta. Oxidative
stress has already been suggested to contribute in the
pathogenesis of placenta-related diseases of pregnancy
such as preeclampsia and miscarriage (17). Various
studies showed increased oxidant status in pregnancies
with both preeclampsia and fetal growth retardation, and
thus suggested that oxidative stress is a major contributor
in preeclampsia- and fetal growth retardation-related
endothelial dysfunction (18,19). Although, to the best of
our knowledge, there are no studies comparing oxidative
stress markers between placenta accreta and healthy
pregnant women, we hypothesized that a mechanism
just the opposite of preeclampsia might have contributed
to the disease process in placenta accreta. In the present
study, we found that oxidative stress was decreased, while
antioxidant status and arylesterase, an antioxidant enzyme,
were increased. Thus, it seems like there is an imbalance
between oxidant and antioxidant mechanisms towards
dominance in antioxidant status in placenta accreta.
McMahon et al. recently demonstrated that lower levels
of placental soluble fms-like tyrosine kinase-1 (sFLT-1)
expression were associated with invasive placentation
(20). sFLT-1 is a potent antiangiogenic growth factor and
an association between increased levels and preeclampsia
has been widely evaluated (21,22). Although sFLT-1 has
been reported to be a predictive marker and important
in the pathophysiology of preeclampsia, the mechanism
of its involvement was recently demonstrated. Jiang et al.
reported that in the serum of sFLT-1 treated preeclamptic
mice, oxidant malonyl dialdehyde levels were higher and
antioxidant superoxide dismutase levels were lower when

compared with controls (23). Hence, they suggested that
sFLT-1 promoted apoptosis by increasing oxidative stress.
Since sFLT-1 levels were reduced in placenta accreta,
it would not be inappropriate to suggest that reduced
sFLT-1 resulted in decreased apoptosis of trophoblasts
and increased angiogenesis, by implication of decreased
oxidative stress. Our study is in agreement with the abovementioned studies, since we found reduced oxidative
stress in placenta accreta.
The antiangiogenic property of the placenta in
preeclampsia and placenta accreta cases is known. Öztürk
et al. observed significantly lower levels of TAS in the
placenta of pregnant patients having preeclampsia when
they were compared with healthy controls, and showed
its significant relation with the maternal serum TAS levels
(24). Moreover, Hilali et al. demonstrated significantly
lower levels of TAS and increased levels of TOS and OSI
in the maternal serum and cord samples of patients having
mild preeclampsia (25).
Recently, Choi et al. suggested that alphafetoprotein
(AFP) is a novel marker protein for the antioxidant effect
of the placenta (26). In addition, it has been already
proposed that unexplained elevated maternal serum
AFP is associated with placenta accreta (1). These studies
confirm the accuracy of our findings, since increased AFP
may be responsible for the increase in antioxidant status in
placenta accreta.
In conclusion, reduced OSI and increased arylesterase
levels are associated with placenta accreta. Decreased
oxidative stress might be either a cause of abnormal
placental invasion or a consequence of increased AFP, and
so this study needs to be validated with further studies
investigating the causal relationship of oxidative stress in
placenta accreta.
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